We have recently shown that low intensity, intermediate frequency, electric fields inhibit by an anti-microtubule mechanism of action, cancerous cell growth in vitro. Using implanted electrodes, these fields were also shown to inhibit the growth of dermal tumors in mice. The present study extends these findings to additional cell lines [human breast carcinoma; MDA-MB-231, and human non-small-cell lung carcinoma (H1299)] and to animal tumor models (intradermal B16F1 melanoma and intracranial F-98 glioma) using external insulated electrodes. These findings led to the initiation of a pilot clinical trial of the effects of TTFields in 10 patients with recurrent glioblastoma (GBM). Median time to disease progression in these patients was 26.1 weeks and median overall survival was 62.2 weeks. These time to disease progression and OS values are more than double the reported medians of historical control patients. No device-related serious adverse events were seen after >70 months of cumulative treatment in all of the patients. The only device-related side effect seen was a mild to moderate contact dermatitis beneath the field delivering electrodes. We conclude that TTFields are a safe and effective new treatment modality which effectively slows down tumor growth in vitro, in vivo and, as demonstrated here, in human cancer patients.

译文

:我们最近发现,低强度,中频电场会通过抗微管作用机制抑制体外癌细胞的生长。使用植入的电极,还显示了这些电场可抑制小鼠皮肤肿瘤的生长。本研究将这些发现扩展到其他细胞系[人乳腺癌; MDA-MB-231和人非小细胞肺癌(H1299)]和动物肿瘤模型(皮内B16F1黑色素瘤和颅内F-98胶质瘤)使用外部绝缘电极。这些发现导致了TTFields在10例复发性胶质母细胞瘤(GBM)患者中的临床试验试验的启动。这些患者疾病进展的中位时间为26.1周,中位总生存期为62.2周。这些疾病进展时间和OS值是历史对照组患者报告中位数的两倍以上。在所有患者中,> 70个月的累积治疗后,均未发现与器械相关的严重不良事件。看到的唯一与设备相关的副作用是在电场传递电极下方的轻度至中度接触性皮炎。我们得出的结论是,TTFields是一种安全有效的新治疗方式,可有效减缓体外,体内以及人类癌症患者体内肿瘤的生长。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录